Advertisement
Product › Details
ADCT-401 (ADC Therapeutics / MedImmune)
Next higher product group | antibody-drug conjugate (ADC) | |
Status | 2014-05-19 development pc planned | |
Organisation | MedImmune (biologics division of AstraZeneca) | |
Group | AstraZeneca (Group) | |
Organisation 2 | ADC Therapeutics S.à.r.l. (ADCT) | |
Today | ADC Therapeutics S.A. (NYSE: ADCT) | |
Group | ADC Therapeutics (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antibody-drug conjugate (ADC)
- [1] GSK plc. (12/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20093". London....
- [2] GSK plc. (10/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20089". London....
- [3] Adcendo ApS. (4/4/23). "Press Release: Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline". Copenhagen....
- [4] Pheon Therapeutics Ltd.. (9/28/22). "Press Release: Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors". London....
- [5] Spirea Ltd.. (6/14/22). "Press Release: Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer". Cambridge....
- [6] Iksuda Therapeutics Ltd.. (6/7/21). "Press Release: Iksuda Therapeutics Closes $47 Million Financing Round". Newcastle....
- [7] Adcendo ApS. (4/29/21). "Press Release: Adcendo Raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers". Copenhagen....
- [8] Pyxis Oncology, Inc.. (3/30/21). "Press Release: Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics". Cambridge, MA....
- [9] Gilead Sciences, Inc.. (1/6/21). "Press Release: Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors". Santa Monica, CA, Oxford & San Jose, CA....
- [10] Arix Bioscience plc. (11/5/20). "Press Release: VelosBio to Be Acquired by Merck for $2.75 Billion". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top